Over 85 firms are involved in providing fragment-based drug discovery-related services; of these, around 40 players claim to offer both libraries and technologies

According to experts in this field, fragment-based drug discovery solutions have facilitated the identification of viable pharmacological leads against otherwise hard to target biomolecules. In fact, many service provider companies are offering fragment libraries and support to the medical research community in order to develop an appropriate intervention to treat the illness caused by the SARS-CoV-2 virus.

• A detailed review of the overall landscape of  fragment-based drug discovery library and service providers along with the information on type of product (library and technology), type of service offered (fragment screening and fragment optimization), type of technique used (X-ray crystallography, nuclear magnetic resonance, surface plasmon resonance, and other screening techniques), other services offered (target identification / validation, hit identification, hit-to-lead / lead generation, lead optimization), and end user (industry, academia, and contract research organizations).
• Elaborate profiles of the companies providing libraries and services for fragment-based drug discovery (shortlisted on the basis of the service portfolio and number of fragment screening techniques offered). Each profile features a brief overview of the company, its financial information (if available), fragment-based library and service portfolio, information on other drug discovery services, recent developments and an informed future outlook.
• An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, mergers and acquisitions, product development and commercialization agreements, commercialization agreements, distribution and supply agreements, product integration agreements, service agreements, and other relevant types of deals.
• A detailed analysis on acquisition targets, taking into consideration the historical trend of the activity of the companies that have acquired other firms since 2015, and offering a means for other industry stakeholders to identify potential acquisition targets.

To order this 170+ page report, which features 55+ figures and 80+ tables, please visit this link

The USD 1.6 billion (by 2030) financial opportunity within the fragment-based drug discovery market has been analyzed across the following segments:

• Type of Screening Technique Used
• X-ray Crystallography
• Nuclear Magnetic Resonance
• Surface Plasmon Resonance
• Other Screening Techniques

• Type of Service Offered

• Library Screening
• Fragment Screening
• Fragment Optimization

• End User

• Industry Players
• Non-Industry Players

• Key geographical regions
• North America (US and Canada)
• Europe (UK, France, Germany, Spain, Italy, and rest of Europe)
• Asia-Pacific (China, Japan, India, and rest of Asia-Pacific / rest of the world)

The Fragment-based Drug Discovery Market: Library and Service Providers, 2020-2030 report features the following companies, which we identified to be key players in this domain:

• 2bind
• Charles River Laboratories
• ChemAxon
• ComInnex
• Creative Biolabs
• Creative Biostructure
• CRELUX
• Domainex
• Evotec
• Red Glead Discovery
• SARomics Biostructures
• Shanghai ChemPartner
• Sygnature Discovery
• Vernalis Research

Table of Contents

Press Release: Variation 3 (Format 4)

1. Preface

2. Executive Summary

3. Introduction
 

4. Current Market Landscape
 

5. Company Profiles: Fragment-based Drug Discovery Library and Service Providers
 

6. Partnerships and Collaborations
 

7. Key Acquisition Targets
 

8. Company Competitiveness Analysis
 

9. Cost Saving Analysis
 

10. Market Forecast and Opportunity Analysis
 

11. Executive Insights

12. Concluding Remarks

13. Appendix 1: Tabulated Data

14. Appendix 2: List of Companies and Organizations

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]